Vorinox
Generic Name
vorinox-200-mg-suspension
Manufacturer
Acme Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| vorinox 200 mg suspension | ৳ 1,000.00 | N/A |
Description
Overview of the medicine
Vorinox (Voriconazole) is a broad-spectrum triazole antifungal agent used to treat serious fungal infections, including invasive aspergillosis, candidemia, and other severe fungal infections. It is available as an oral suspension.
Uses & Indications
Dosage
Adults
Loading dose: 400 mg (10 mL) every 12 hours for 2 doses, then Maintenance dose: 200 mg (5 mL) every 12 hours. Dosage should be adjusted based on weight for children and may vary. For suspension, it's typically 200mg/5mL.
Elderly
No specific dose adjustment generally required, but caution due to potential age-related decrease in hepatic function.
Renal_impairment
No dose adjustment needed for oral administration. Avoid intravenous formulation due to excipient accumulation.
How to Take
Oral suspension should be taken at least one hour before or one hour after a meal. Shake well before use. Use the provided measuring device for accurate dosing.
Mechanism of Action
Voriconazole inhibits fungal cytochrome P-450-mediated 14α-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis. Ergosterol is a critical component of the fungal cell membrane; its reduced synthesis leads to increased cellular permeability and eventual cell death.
Pharmacokinetics
Onset
Variable, generally within hours of administration.
Excretion
Primarily renal (80% as metabolites), less than 2% excreted unchanged in urine.
Half life
Dose-dependent, ranging from 6 to 12 hours after single oral doses.
Absorption
Rapid and almost complete oral absorption; bioavailability of about 90%. Peak plasma concentrations achieved within 1-2 hours.
Metabolism
Primarily hepatic, via cytochrome P450 enzymes (CYP2C19, CYP2C9, and CYP3A4). Extensive metabolism.
Side Effects
Contraindications
- •Hypersensitivity to voriconazole or any component of the formulation.
- •Coadministration with CYP3A4 substrates that prolong the QT interval (e.g., cisapride, pimozide, quinidine).
- •Coadministration with efavirenz, carbamazepine, rifampin, rifabutin, long-acting barbiturates, or ergot alkaloids.
Drug Interactions
Warfarin
Increased anticoagulant effect, monitor INR.
Efavirenz
Contraindicated, leads to significant decrease in voriconazole levels.
Phenytoin
Significant decrease in voriconazole levels; requires dose adjustment.
Cyclosporine, Tacrolimus
Increased immunosuppressant levels, monitor and adjust dose.
Benzodiazepines (e.g., Midazolam)
Increased benzodiazepine levels, leading to increased sedation.
Storage
Store dry powder at controlled room temperature (20-25°C). Do not freeze. Keep the bottle tightly closed. After reconstitution, store in the refrigerator (2-8°C).
Overdose
No specific antidote. Management is supportive and symptomatic. Hemodialysis is not effective for voriconazole elimination.
Pregnancy & Lactation
Category D in pregnancy (potential fetal harm). Should be used only if the benefit outweighs the risk. Avoid breastfeeding during treatment due to potential harm to infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Unreconstituted powder: 24-36 months. Reconstituted suspension: 14 days at 2-8°C.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Off-patent (active ingredient)
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
